The long-term management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is complicated by the presence of co-existing medical conditions and the unpredictable nature of disease relapse.

• Comorbidities: As CIDP disproportionately affects the elderly, patients frequently have comorbidities such as diabetes, hypertension, and cardiovascular disease. These conditions significantly influence treatment choice; for instance, diabetes and hypertension make long-term corticosteroid use highly undesirable. Furthermore, conditions like diabetes can cause other neuropathies, complicating the CIDP diagnosis itself.

• Relapse Management: Acute relapse, defined as a clinical deterioration requiring a change in treatment, requires immediate action. Strategies typically involve a temporary increase in the dose or frequency of the current maintenance therapy (e.g., increased IVIG dose) or a brief course of high-dose corticosteroids. Effective long-term management focuses on identifying and treating potential triggers for relapse and maintaining consistent, optimized maintenance therapy to prevent functional decline in the CIDP Market, as detailed in comprehensive care guidelines, such as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook.